Citations

Guerci P, Vidal O, Guinot PG, Klein T. Preventing Iatrogenic Euglycemic Diabetic Ketoacidosis in Cardiac Surgery: The Role of Sodium-Glucose Cotransporter 2 Inhibitors. J Cardiothorac Vasc Anesth. 2023 Oct;37(10):2159. doi: 10.1053/j.jvca.2023.06.029. Epub 2023 Jun 24. PMID: 37453809.
Link to Article
Link to FULL FREE PDF

Auerbach JS, Gershengorn HB, Aljure OD, Lamelas J, Patel SS, Ferreira TD, Gonzalez LA, Cabrera JL. Postcardiac Surgery Euglycemic Diabetic Ketoacidosis in Patients on Sodium-Glucose Cotransporter 2 Inhibitors. J Cardiothorac Vasc Anesth. 2023 Jun;37(6):956-963. doi: 10.1053/j.jvca.2023.01.041. Epub 2023 Feb 7. PMID: 36872114.
Link to (NOT FREE) Article

Branco A, Fatima R, Liblik K, Jackson R, Payne D, El-Diasty M. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter-2 Inhibitors After Cardiac Surgery: A Review of Current Literature. J Cardiothorac Vasc Anesth. 2022 Oct;36(10):3877-3886. doi: 10.1053/j.jvca.2022.06.008. Epub 2022 Jun 16. PMID: 35863986.
Link to (NOT FREE) Article

Mehta PB, Robinson A, Burkhardt D, Rushakoff RJ. Inpatient Perioperative Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter-2 Inhibitors – Lessons From a Case Series and Strategies to Decrease Incidence. Endocr Pract. 2022 Sep;28(9):884-888. doi: 10.1016/j.eprac.2022.06.006. Epub 2022 Jun 23. PMID: 35753675.
Link to Article
Link to FULL FREE PDF

Chaudhry A, Roels C, Lee J. Sodium-Glucose Cotransporter-2 Inhibitor-associated Euglycemic Diabetic Ketoacidosis: Lessons From a Case Series of 4 Patients Undergoing Coronary Artery Bypass Grafting Surgery. Can J Diabetes. 2022 Dec;46(8):843-850. doi: 10.1016/j.jcjd.2022.06.007. Epub 2022 Jun 23. PMID: 36068154.
Link to (NOT FREE) Article

Wohlrab P, Kainz M, Schiferer A, Zapletal B, Tschernko E. Euglycemic Diabetic Ketoacidosis After Cardiac Surgery in a Patient Treated With Empagliflozin for Type 2 Diabetes Mellitus. J Cardiothorac Vasc Anesth. 2022 Jul;36(7):2066-2069. doi: 10.1053/j.jvca.2021.07.048. Epub 2021 Jul 31. PMID: 34465512.
Link to (NOT FREE) Article

Lau A, Bruce S, Wang E, Ree R, Rondi K, Chau A. Perioperative implications of sodium-glucose cotransporter-2 inhibitors: a case series of euglycemic diabetic ketoacidosis in three patients after cardiac surgery. Can J Anaesth. 2018 Feb;65(2):188-193. English. doi: 10.1007/s12630-017-1018-6. Epub 2017 Nov 22. PMID: 29168157.
Link to Article
Link to FULL FREE PDF

Pontes JPJ, de Melo CS, Arantes FBB, de Souza Ramos JTG, Módolo NSP, Navarro E Lima LH. Perioperative euglycemic diabetic ketoacidosis following use of SGLT-2 inhibitors after cardiac surgery. J Clin Anesth. 2021 Aug;71:110201. doi: 10.1016/j.jclinane.2021.110201. Epub 2021 Feb 26. PMID: 33647525.
Link to (NOT FREE) Article

Kim HA, Kim JY, Kim YH, Lee YT, Park PW. Missed postoperative metabolic acidosis associated with sodium-glucose transporter 2 inhibitors in cardiac surgery patients: a retrospective analysis. Sci Rep. 2024 Apr 6;14(1):8087. doi: 10.1038/s41598-024-58853-7. PMID: 38582803; PMCID: PMC10998860.
Link to Article
Link to FULL FREE PDF

Murugesan KB, Balakrishnan S, Arul A, Ramalingam S, Srinivasan M. A retrospective analysis of the incidence, outcome and factors associated with the occurrence of euglycemic ketoacidosis in diabetic patients on sodium glucose co-transporter – 2 inhibitors undergoing cardiac surgery. Ann Card Anaesth. 2022 Oct-Dec;25(4):460-465. doi: 10.4103/aca.aca_47_21. PMID: 36254911; PMCID: PMC9732953.
Link to Article
Link to FULL FREE PDF

McCann M, O’Brien A, Larbalestier R, Davis T. Sodium-glucose cotransport-2 inhibitor induced ketoacidosis following coronary artery bypass surgery: implications for management. Intern Med J. 2022 May;52(5):876-879. doi: 10.1111/imj.15772. PMID: 35538006. (MISSING)
Link to (NOT FREE) Article

Smyth CC, Collins M, McCarthy J, Galvin S. The catabolic triad: case report of fasting, major cardiac surgery and sodium-glucose co-transporter 2 inhibitors leading to perioperative euglycaemic ketoacidosis. Interact Cardiovasc Thorac Surg. 2021 Aug 18;33(3):494-495. doi: 10.1093/icvts/ivab104. PMID: 33961026; PMCID: PMC8691577.
Link to Article
Link to FULL FREE PDF

FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Food and Drug Administration. http://www.fda.gov/Drugs/DrugSafety/ucm475463.
htm (2021).

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19. PMID: 31535829.
Link to Article
Link to FULL FREE PDF

Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F; EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28. PMID: 32865377.
Link to Article
Link to FULL FREE PDF

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27. PMID: 34449189.
Link to Article
Link to FULL FREE PDF

Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O’Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderäng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM; DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022 Sep 22;387(12):1089-1098. doi: 10.1056/NEJMoa2206286. Epub 2022 Aug 27. PMID: 36027570.
Link to Article
Link to FULL FREE PDF

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. Erratum in: Eur Heart J. 2021 Dec 21;42(48):4901. doi: 10.1093/eurheartj/ehab670. PMID: 34447992.
Link to Article
Link to FULL FREE PDF

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1. Erratum in: Circulation. 2022 May 3;145(18):e1033. doi: 10.1161/CIR.0000000000001073. Erratum in: Circulation. 2022 Sep 27;146(13):e185. doi: 10.1161/CIR.0000000000001097. Erratum in: Circulation. 2023 Apr 4;147(14):e674. doi: 10.1161/CIR.0000000000001142. PMID: 35363499.
Link to Article
Link to FULL FREE PDF